David H Gutmann

List of Publications by Year
in descending order

511 papers	44,660 citations	2093 100 h-index	3257 185 g-index
530 all docs	530 docs citations	530 times ranked	36601 citing authors

#	Article	IF	Citations
1	The Somatic Genomic Landscape of Glioblastoma. Cell, 2013, 155, 462-477.	13.5	3,979
2	Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell, 2016, 164, 550-563.	13.5	1,695
3	The role of microglia and macrophages in glioma maintenance and progression. Nature Neuroscience, 2016, 19, 20-27.	7.1	1,148
4	The Diagnostic Evaluation and Multidisciplinary Management of Neurofibromatosis 1 and Neurofibromatosis 2. JAMA - Journal of the American Medical Association, 1997, 278, 51.	3.8	1,030
5	Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nature Neuroscience, 2008, 11, 251-253.	7.1	1,015
6	Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell, 2017, 171, 950-965.e28.	13.5	738
7	Subtypes of medulloblastoma have distinct developmental origins. Nature, 2010, 468, 1095-1099.	13.7	710
8	Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature, 1992, 356, 713-715.	13.7	653
9	Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Annals of Neurology, 2008, 63, 444-453.	2.8	563
10	Neurofibromatosis Type 1 Revisited. Pediatrics, 2009, 123, 124-133.	1.0	562
11	Challenges to curing primary brain tumours. Nature Reviews Clinical Oncology, 2019, 16, 509-520.	12.5	540
12	Optic pathway gliomas in neurofibromatosis-1: Controversies and recommendations. Annals of Neurology, 2007, 61, 189-198.	2.8	531
13	Neurofibromatosis type 1. Nature Reviews Disease Primers, 2017, 3, 17004.	18.1	498
14	The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes and Development, 2001, 15, 968-980.	2.7	468
15	Cellular and Molecular Identity of Tumor-Associated Macrophages in Glioblastoma. Cancer Research, 2017, 77, 2266-2278.	0.4	463
16	International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Research, 2002, 62, 1573-7.	0.4	438
17	Optic pathway gliomas in children with neurofibromatosis 1: Consensus statement from the nf1 optic pathway glioma task force. Annals of Neurology, 1997, 41, 143-149.	2.8	434
18	Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurology, The, 2014, 13, 834-843.	4.9	405

#	Article	IF	Citations
19	cDNA cloning of the type 1 neurofibromatosis gene: Complete sequence of the NF1 gene product. Genomics, 1991, 11, 931-940.	1.3	384
20	Neurofibromin Regulation of ERK Signaling Modulates GABA Release and Learning. Cell, 2008, 135, 549-560.	13.5	384
21	The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA - Journal of the American Medical Association, 1997, 278, 51-7.	3.8	375
22	Cardiovascular disease in neurofibromatosis 1: Report of the NF1 Cardiovascular Task Force. Genetics in Medicine, 2002, 4, 105-111.	1.1	330
23	Astrocyte-specificTSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures. Annals of Neurology, 2002, 52, 285-296.	2.8	330
24	Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genetics in Medicine, 2021, 23, 1506-1513.	1.1	290
25	Proteomic Analysis Reveals Hyperactivation of the Mammalian Target of Rapamycin Pathway in Neurofibromatosis 1â€“Associated Human and Mouse Brain Tumors. Cancer Research, 2005, 65, 2755-2760.	0.4	283
26	Astrocyte-Specific Inactivation of the Neurofibromatosis 1 Gene (NF1) Is Insufficient for Astrocytoma Formation. Molecular and Cellular Biology, 2002, 22, 5100-5113.	1.1	266
27	Identification of the neurofibromatosis type 1 gene product.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 9658-9662.	3.3	264
28	Molecular pathogenesis of meningiomas. Journal of Neuro-Oncology, 2004, 70, 183-202.	1.4	252
29	Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro-Oncology, 2012, 14, 790-797.	0.6	248
30	Oncogenic BRAF Mutation with CDKN2A Inactivation Is Characteristic of a Subset of Pediatric Malignant Astrocytomas. Cancer Research, 2010, 70, 512-519.	0.4	236
31	Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Research, 2003, 63, 8573-7.	0.4	221
32	Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene, 1997, 15, 2505-2509.	2.6	212
33	Pten Loss Causes Hypertrophy and Increased Proliferation of Astrocytes In vivo. Cancer Research, 2004, 64, 7773-7779.	0.4	204
34	Differential Effects of cAMP in Neurons and Astrocytes. Journal of Biological Chemistry, 1999, 274, 25842-25848.	1.6	201
35	Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes and Development, 2002, 16, 1060-1065.	2.7	201
36	Aggressive Phenotypic and Genotypic Features in Pediatric and NF2-Associated Meningiomas: A Clinicopathologic Study of 53 Cases. Journal of Neuropathology and Experimental Neurology, 2001, 60, 994-1003.	0.9	194

#	Article	IF	Citations
37	Large-Scale Molecular Comparison of Human Schwann Cells to Malignant Peripheral Nerve Sheath Tumor Cell Lines and Tissues. Cancer Research, 2006, 66, 2584-2591.	0.4	191
38	Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of Tuberous Sclerosis Complex. Human Molecular Genetics, 2011, 20, 445-454.	1.4	191
39	Microglia/Brain Macrophages as Central Drivers of Brain Tumor Pathobiology. Neuron, 2019, 104, 442-449.	3.8	190
40	Integrative Genomic Analysis Identifies NDRG2 as a Candidate Tumor Suppressor Gene Frequently Inactivated in Clinically Aggressive Meningioma. Cancer Research, 2005, 65, 7121-7126.	0.4	187
41	Malignant peripheral nerve sheath tumors in neurofibromatosis 1. American Journal of Medical Genetics Part A, 2000, 93, 388-392.	2.4	182
42	Roadmap for the Emerging Field of Cancer Neuroscience. Cell, 2020, 181, 219-222.	13.5	182
43	Neurofibromatosis-1 Regulates Neuronal and Glial Cell Differentiation from Neuroglial Progenitors InÂVivo by Both cAMP- and Ras-Dependent Mechanisms. Cell Stem Cell, 2007, 1, 443-457.	5.2	180
44	Oligodendroglial myelination requires astrocyte-derived lipids. PLoS Biology, 2017, 15, e1002605.	2.6	179
45	Impaired glial glutamate transport in a mouse tuberous sclerosis epilepsy model. Annals of Neurology, 2003, 54, 251-256.	2.8	176
46	Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth. Human Molecular Genetics, 2007, 16, 1098-1112.	1.4	169
47	Neurofibromatosis type 1 (NF1). Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 115, 939-955.	1.0	169
48	Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. Development (Cambridge), 2005, 132, 5577-5588.	1.2	166
49	Distinct Genetic Signatures among Pilocytic Astrocytomas Relate to Their Brain Region Origin. Cancer Research, 2007, 67, 890-900.	0.4	164
50	Gliomas in Neurofibromatosis Type 1: A Clinicopathologic Study of 100 Patients. Journal of Neuropathology and Experimental Neurology, 2008, 67, 240-249.	0.9	162
51	Protein 4.1 tumor suppressors: getting a FERM grip on growth regulation. Journal of Cell Science, 2002, 115, 3991-4000.	1.2	161
52	Astrocyte loss of mutant SOD1 delays ALS disease onset and progression in G85R transgenic mice. Human Molecular Genetics, 2011, 20, 286-293.	1.4	161
53	Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas. Human Molecular Genetics, 2000, 9, 1495-1500.	1.4	160
54	Nectin-like proteins mediate axonâ€“Schwann cell interactions along the internode and are essential for myelination. Journal of Cell Biology, 2007, 178, 861-874.	2.3	158

#	Article	IF	Citations
55	Loss of merlin expression in sporadic meningiomas, ependymomas and schwannomas. Neurology, 1997, 49, 267-270.	1.5	156
56	The neurofibromatosis type 1 gene and its protein product, neurofibromin. Neuron, 1993, 10, 335-343.	3.8	151
57	Merlin, DAL-1, and Progesterone Receptor Expression in Clinicopathologic Subsets of Meningioma: A Correlative Immunohistochemical Study of 175 Cases. Journal of Neuropathology and Experimental Neurology, 2000, 59, 872-879.	0.9	150
58	BRAFV600E mutation is a negative prognosticator in pediatric ganglioglioma. Acta Neuropathologica, 2013, 125, 901-910.	3.9	149
59	Mutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines. Nature Genetics, 1993, 3, 118-121.	9.4	147
60	Merlin differentially associates with the microtubule and actin cytoskeleton. , 1998, 51, 403-415.		146
61	Intracranial gliomas in neurofibromatosis type 1. , 1999, 89, 38-44.		146
62	Loss of neurofibromatosis 1 (NF1) gene expression in NF1-associated pilocytic astrocytomas. Neuropathology and Applied Neurobiology, 2000, 26, 361-367.	1.8	142
63	Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1). Neurology, 2002, 59, 759-761.	1.5	139
64	The Neurofibromatosis 1 Gene Product Neurofibromin Regulates Pituitary Adenylate Cyclase-Activating Polypeptide-Mediated Signaling in Astrocytes. Journal of Neuroscience, 2003, 23, 8949-8954.	1.7	139
65	Optic pathway gliomas in neurofibromatosis type 1: The effect of presenting symptoms on outcome. American Journal of Medical Genetics Part A, 2003, 122A, 95-99.	2.4	137
66	Neurofibromatosis type 1. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2015, 132, 75-86.	1.0	137
67	Expression of ICAM-1, TNF-Î±, NFÎºB, and MAP kinase in tubers of the tuberous sclerosis complex. Neurobiology of Disease, 2003, 14, 279-290.	2.1	134
68	Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 18200-18205.	3.3	134
69	Morphologic and immunohistochemical features of malignant peripheral nerve sheath tumors and cellular schwannomas. Modern Pathology, 2015, 28, 187-200.	2.9	134
70	Loss of Neurofibromin Is Associated with Activation of RAS/MAPK and PI3-K/AKT Signaling in a Neurofibromatosis 1 Astrocytoma. Journal of Neuropathology and Experimental Neurology, 2000, 59, 759-767.	0.9	133
71	Identification of a progenitor cell of origin capable of generating diverse meningioma histological subtypes. Oncogene, 2011, 30, 2333-2344.	2.6	133
72	The Neurofibromatosis 2 Tumor Suppressor Gene Product, Merlin, Regulates Human Meningioma Cell Growth by Signaling through YAP. Neoplasia, 2008, 10, 1204-1212.	2.3	130

#	Article	IF	Citations
73	Preclinical Cancer Therapy in a Mouse Model of Neurofibromatosis-1 Optic Glioma. Cancer Research, 2008, 68, 1520-1528.	0.4	130
74	Astrocyte gp130 Expression Is Critical for the Control of Toxoplasma Encephalitis. Journal of Immunology, 2008, 181, 2683-2693.	0.4	126
75	NF1 Deletions in S-100 Protein-Positive and Negative Cells of Sporadic and Neurofibromatosis 1 (NF1)-Associated Plexiform Neurofibromas and Malignant Peripheral Nerve Sheath Tumors. American Journal of Pathology, 2001, 159, 57-61.	1.9	124
76	Comprehensive gene expression meta-analysis identifies signature genes that distinguish microglia from peripheral monocytes/macrophages in health and glioma. Acta Neuropathologica Communications, 2019, 7, 20.	2.4	124
77	Neurofibromatosis type 1 gene product (neurofibromin) associates with microtubules. Somatic Cell and Molecular Genetics, 1993, 19, 265-274.	0.7	123
78	Neurofibromin Regulates Neural Stem Cell Proliferation, Survival, and Astroglial Differentiation In Vitro and In Vivo. Journal of Neuroscience, 2005, 25, 5584-5594.	1.7	120
79	Astrocyte-Derived Vascular Endothelial Growth Factor Stabilizes Vessels in the Developing Retinal Vasculature. PLoS ONE, 2010, 5, e11863.	1.1	120
80	The adhesion GPCR Gpr56 regulates oligodendrocyte development via interactions with GÎ±12/13 and RhoA. Nature Communications, 2015, 6, 6122.	5.8	119
81	Clinic-based study of plexiform neurofibromas in neurofibromatosis 1. American Journal of Medical Genetics Part A, 2000, 92, 132-135.	2.4	118
82	Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a Neurofibromatosis Clinical Trials Consortium phase II study. Neuro-Oncology, 2015, 17, 596-603.	0.6	118
83	Immunohistochemical Analysis Supports a Role for INI1/SMARCB1 in Hereditary Forms of Schwannomas, but Not in Solitary, Sporadic Schwannomas. Brain Pathology, 2008, 18, 517-519.	2.1	117
84	Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice. Human Molecular Genetics, 2010, 19, 4515-4528.	1.4	117
85	Abnormal glutamate homeostasis and impaired synaptic plasticity and learning in a mouse model of tuberous sclerosis complex. Neurobiology of Disease, 2007, 28, 184-196.	2.1	116
86	Integrin-dependent and -independent functions of astrocytic fibronectin in retinal angiogenesis. Development (Cambridge), 2011, 138, 4451-4463.	1.2	116
87	Optic Pathway Gliomas in Neurofibromatosis Type 1. Journal of Child Neurology, 2018, 33, 73-81.	0.7	116
88	Recent advances in neurofibromatosis type 1. Current Opinion in Neurology, 2004, 17, 101-105.	1.8	114
89	Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1. Annals of Neurology, 2014, 75, 309-316.	2.8	114
90	Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation. Oncogene, 1999, 18, 4450-4459.	2.6	113

#	Article	IF	Citations
91	Epileptogenesis and Reduced Inward Rectifier Potassium Current in Tuberous Sclerosis Complex-1-Deficient Astrocytes. Epilepsia, 2005, 46, 1871-1880.	2.6	113
92	Regulated temporal-spatial astrocyte precursor cell proliferation involves BRAF signalling in mammalian spinal cord. Development (Cambridge), 2012, 139, 2477-2487.	1.2	112
93	Molecular Characterization of Human Meningiomas by Gene Expression Profiling Using High-Density Oligonucleotide Microarrays. American Journal of Pathology, 2002, 161, 665-672.	1.9	110
94	Serine 518 phosphorylation modulates merlin intramolecular association and binding to critical effectors important for NF2 growth suppression. Oncogene, 2004, 23, 8447-8454.	2.6	110
95	Neurofibromatosis-1 Heterozygosity Increases Microglia in a Spatially and Temporally Restricted Pattern Relevant to Mouse Optic Glioma Formation and Growth. Journal of Neuropathology and Experimental Neurology, 2011, 70, 51-62.	0.9	110
96	Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a RAS transgenic mouse astrocytoma model. Cancer Research, 2003, 63, 1106-13.	0.4	109
97	Increased expression of the NF2 tumor suppressor gene product, merlin, impairs cell motility, adhesionand spreading. Human Molecular Genetics, 1999, 8, 267-275.	1.4	108
98	DifferentialNF1,p16, andEGFRPatterns by Interphase Cytogenetics (FISH) in Malignant Peripheral Nerve Sheath Tumor (MPNST) and Morphologically Similar Spindle Cell Neoplasms. Journal of Neuropathology and Experimental Neurology, 2002, 61, 702-709.	0.9	108
99	Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)â€regulated glial proliferation. Glia, 2009, 57, 1239-1249.	2.5	108
100	Microglia as Dynamic Cellular Mediators of Brain Function. Trends in Molecular Medicine, 2019, 25, 967-979.	3.5	107
101	Neurofibromatosis 2. Current Opinion in Neurology, 2003, 16, 27-33.	1.8	106
102	The neurofibromatoses: when less is more. Human Molecular Genetics, 2001, 10, 747-755.	1.4	105
103	Identification of Dominant Negative Mutants of Rheb GTPase and Their Use to Implicate the Involvement of Human Rheb in the Activation of p70S6K. Journal of Biological Chemistry, 2003, 278, 39921-39930.	1.6	105
104	Spatiotemporal Differences in CXCL12 Expression and Cyclic AMP Underlie the Unique Pattern of Optic Glioma Growth in Neurofibromatosis Type 1. Cancer Research, 2007, 67, 8588-8595.	0.4	105
105	Increased c-Jun-NH2-Kinase Signaling in Neurofibromatosis-1 Heterozygous Microglia Drives Microglia Activation and Promotes Optic Glioma Proliferation. Cancer Research, 2008, 68, 10358-10366.	0.4	105
106	Array-Based Comparative Genomic Hybridization Identifies CDK4 and FOXM1 Alterations as Independent Predictors of Survival in Malignant Peripheral Nerve Sheath Tumor. Clinical Cancer Research, 2011, 17, 1924-1934.	3.2	103
107	Functional outcome measures for NF1-associated optic pathway glioma clinical trials. Neurology, 2013, 81, S15-24.	1.5	103
108	Neurofibromatosis-1 regulates neuroglial progenitor proliferation and glial differentiation in a brain region-specific manner. Genes and Development, 2010, 24, 2317-2329.	2.7	102

#	Article	IF	Citations
109	Cyclic AMP Suppression Is Sufficient to Induce Gliomagenesis in a Mouse Model of Neurofibromatosis-1. Cancer Research, 2010, 70, 5717-5727.	0.4	102
110	High-Grade Glioma Formation Results from Postnatal Pten Loss or Mutant Epidermal Growth Factor Receptor Expression in a Transgenic Mouse Glioma Model. Cancer Research, 2006, 66, 7429-7437.	0.4	101
111	Defective cAMP Generation Underlies the Sensitivity of CNS Neurons to Neurofibromatosis-1 Heterozygosity. Journal of Neuroscience, 2010, 30, 5579-5589.	1.7	100
112	DAL-1/4.1B tumor suppressor interacts with protein arginine N-methyltransferase 3 (PRMT3) and inhibits its ability to methylate substrates in vitro and in vivo. Oncogene, 2004, 23, 7761-7771.	2.6	99
113	Somatic neurofibromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma. Genome Research, 2013, 23, 431-439.	2.4	99
114	Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision. Journal of Neuro-Ophthalmology, 2017, 37, S23-S32.	0.4	99
115	Merlin Is a Potent Inhibitor of Glioma Growth. Cancer Research, 2008, 68, 5733-5742.	0.4	97
116	High-resolution, dual-platform aCGH analysis reveals frequent HIPK2 amplification and increased expression in pilocytic astrocytomas. Oncogene, 2008, 27, 4745-4751.	2.6	96
117	Neurofibromatosis 1. Neurologic Clinics, 2002, 20, 841-865.	0.8	95
118	Predictive Value of CafÃ© au Lait Macules at Initial Consultation in the Diagnosis of Neurofibromatosis Type 1. Archives of Dermatology, 2009, 145, 883-7.	1.7	95
119	Innate Neural Stem Cell Heterogeneity Determines the Patterning of Glioma Formation in Children. Cancer Cell, 2012, 22, 131-138.	7.7	95
120	Neurofibromatosis 1: closing the GAP between mice and men. Current Opinion in Genetics and Development, 2003, 13, 20-27.	1.5	91
121	Effect of merlin phosphorylation on neurofibromatosis 2 (NF2) gene function. Oncogene, 2004, 23, 580-587.	2.6	91
122	Reduced microglial <scp>CX3CR1</scp> expression delays neurofibromatosisâ€1 glioma formation. Annals of Neurology, 2013, 73, 303-308.	2.8	91
123	NF1 mutation drives neuronalÂactivity-dependent initiation of optic glioma. Nature, 2021, 594, 277-282.	13.7	91
124	BRAF-V600E mutation in pediatric and adult glioblastoma. Neuro-Oncology, 2014, 16, 318-319.	0.6	90
125	Disease Burden and Symptom Structure of Autism in Neurofibromatosis Type 1. JAMA Psychiatry, 2016, 73, 1276.	6.0	90
126	Neurofibromatosis Type 1: Modeling CNS Dysfunction. Journal of Neuroscience, 2012, 32, 14087-14093.	1.7	88

#	Article	IF	Citations
127	Advances in the treatment of neurofibromatosis-associated tumours. Nature Reviews Clinical Oncology, 2013, 10, 616-624.	12.5	88
128	Expression of the neurofibromatosis I gene product, neurofibromin, in blood vessel endothelial cells and smooth muscle. Neurobiology of Disease, 1995, 2, 13-21.	2.1	87
129	Neurofibromatosis 1: From lab bench to clinic. Pediatric Neurology, 2005, 32, 221-228.	1.0	87
130	Molecular analysis of astrocytomas presenting after age 10 in individuals with NF1. Neurology, 2003, 61, 1397-1400.	1.5	85
131	Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC/Rheb-independent manner. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 15996-16001.	3.3	85
132	Mixed-lineage kinase 3 regulates B-Raf through maintenance of the B-Raf/Raf-1 complex and inhibition by the NF2 tumor suppressor protein. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 4463-4468.	3.3	84
133	Pediatric glioma-associated KIAA1549:BRAF expression regulates neuroglial cell growth in a cell type-specific and mTOR-dependent manner. Genes and Development, 2012, 26, 2561-2566.	2.7	84
134	Neurofibromatosis type 1. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 148, 799-811.	1.0	84
135	Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma. International Journal of Cancer, 2008, 123, 2080-2086.	2.3	83
136	Midkine activation of CD8+ T cells establishes a neuronâ€“immuneâ€“cancer axis responsible for low-grade glioma growth. Nature Communications, 2020, 11, 2177.	5.8	83
137	Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. Cancer Research, 2005, 65, 236-45.	0.4	83
138	Defects in neurofibromatosis 2 protein function can arise at multiple levels. Human Molecular Genetics, 1998, 7, 335-345.	1.4	82
139	Akt phosphorylation regulates the tumour-suppressor merlin through ubiquitination and degradation. Nature Cell Biology, 2007, 9, 1199-1207.	4.6	82
140	Modeling cognitive dysfunction in neurofibromatosis-1. Trends in Neurosciences, 2013, 36, 237-247.	4.2	82
141	Neurofibromatosis type 1 â€" a model for nervous system tumour formation?. Nature Reviews Cancer, 2005, 5, 557-564.	12.8	81
142	Deconvoluting mTOR biology. Cell Cycle, 2012, 11, 236-248.	1.3	80
143	Neurofibromatosis Type 1â€“Associated MPNST State of the Science: Outlining a Research Agenda for the Future. Journal of the National Cancer Institute, 2017, 109, .	3.0	80
144	Identification of a third Protein 4.1 tumor suppressor, Protein 4.1R, in meningioma pathogenesis. Neurobiology of Disease, 2003, 13, 191-202.	2.1	78

#	Article	IF	Citations
145	T-Cadherin-Mediated Cell Growth Regulation Involves G 2 Phase Arrest and Requires p21 CIP1/WAF1 Expression. Molecular and Cellular Biology, 2003, 23, 566-578.	1.1	78
146	Optimizing biologically targeted clinical trials for neurofibromatosis. Expert Opinion on Investigational Drugs, 2013, 22, 443-462.	1.9	77
147	Expression of the neurofibromatosis 2 tumor suppressor gene product, merlin, in Schwann cells. Journal of Neuroscience Research, 1996, 46, 595-605.	1.3	76
148	Meningioma: an update. Current Opinion in Neurology, 2004, 17, 687-692.	1.8	76
149	Epilepsy in individuals with neurofibromatosis type 1. Epilepsia, 2013, 54, 1810-1814.	2.6	76
150	Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1. Neurology, 2016, 87, 2575-2584.	1.5	76
151	RAS pathway activation and an oncogenic RAS mutation in sporadic pilocytic astrocytoma. Neurology, 2005, 65, 1335-1336.	1.5	75
152	Histopathologic predictors of pilocytic astrocytoma event-free survival. Acta Neuropathologica, 2009, 117, 657-665.	3.9	75
153	Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth. Neuro-Oncology, 2015, 17, 843-853.	0.6	75
154	RNA Sequencing of Tumor-Associated Microglia Reveals Ccl5 as a Stromal Chemokine Critical for Neurofibromatosis-1 Glioma Growth. Neoplasia, 2015, 17, 776-788.	2.3	75
155	An alternatively-spliced mRNA in the carboxy terminus of the neurofibromatosis type 1 (NF1) gene is expressed in muscle. Human Molecular Genetics, 1993, 2, 989-992.	1.4	74
156	Heterozygosity for the tuberous sclerosis complex (TSC) gene products results in increased astrocyte numbers and decreased p27-Kip1 expression in TSC2+/â˜' cells. Oncogene, 2002, 21, 4050-4059.	2.6	74
157	Phosphorylation of neurofibromin by PKC is a possible molecular switch in EGF receptor signaling in neural cells. Oncogene, 2006, 25, 735-745.	2.6	74
158	Ezrin, radixin, and moesin are components of Schwann cell microvilli. Journal of Neuroscience Research, 2001, 65, 150-164.	1.3	73
159	Sirolimus for nonâ€progressive NF1â€associated plexiform neurofibromas: An NF clinical trials consortium phase II study. Pediatric Blood and Cancer, 2014, 61, 982-986.	0.8	73
160	Gene Expression Profiling Reveals Unique Molecular Subtypes of Neurofibromatosis Type Iâ€associated and Sporadic Malignant Peripheral Nerve Sheath Tumors. Brain Pathology, 2004, 14, 297-303.	2.1	72
161	Visual acuity in children with low grade gliomas of the visual pathway: implications for patient care and clinical research. Journal of Neuro-Oncology, 2012, 110, 1-7.	1.4	72
162	Promoter hypermethylation of the potential tumor suppressorDAL-1/4.1Bgene in renal clear cell carcinoma. International Journal of Cancer, 2006, 118, 916-923.	2.3	71

#	Article	IF	Citations
163	ABCA1 influences neuroinflammation and neuronal death. Neurobiology of Disease, 2013, 54, 445-455.	2.1	71
164	Tumorigenesis in neurofibromatosis: new insights and potential therapies. Trends in Molecular Medicine, 2001, 7, 157-162.	3.5	70
165	The Neurofibromatosis 2 Protein, Merlin, Regulates Glial Cell Growth in an ErbB2- and Src-Dependent Manner. Molecular and Cellular Biology, 2009, 29, 1472-1486.	1.1	70
166	Elucidating the impact of neurofibromatosis-1 germline mutations on neurofibromin function and dopamine-based learning. Human Molecular Genetics, 2015, 24, 3518-3528.	1.4	70
167	CNS Tumors in Neurofibromatosis. Journal of Clinical Oncology, 2017, 35, 2378-2385.	0.8	70
168	Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation. Glia, 2004, 47, 180-188.	2.5	69
169	Neurofibromatosis 1 (NF1) heterozygosity results in a cell-autonomous growth advantage for astrocytes. Glia, 2001, 33, 314-323.	2.5	68
170	Dopamine deficiency underlies learning deficits in neurofibromatosisâ€1 mice. Annals of Neurology, 2013, 73, 309-315.	2.8	68
171	Loss of neurofibromin in adrenal gland tumors from patients with neurofibromatosis type I. Genes Chromosomes and Cancer, 1994, 10, 55-58.	1.5	67
172	Neurofibromatosis Type 1: Piecing the Puzzle Together. Canadian Journal of Neurological Sciences, 1998, 25, 181-191.	0.3	67
173	Natural history of neurofibromatosis 1-associated optic nerve glioma in mice. Annals of Neurology, 2005, 57, 119-127.	2.8	67
174	Axonal integrity in the absence of functional peroxisomes from projection neurons and astrocytes. Glia, 2010, 58, 1532-1543.	2.5	67
175	Neuronal NF1/RAS regulation of cyclic AMP requires atypical PKC activation. Human Molecular Genetics, 2014, 23, 6712-6721.	1.4	67
176	Comparative gene expression profile analysis of neurofibromatosis 1-associated and sporadic pilocytic astrocytomas. Cancer Research, 2002, 62, 2085-91.	0.4	67
177	The Neurofibromatosis Type 1 Tumor Suppressor Controls Cell Growth by Regulating Signal Transducer and Activator of Transcription-3 Activity In vitro and In vivo. Cancer Research, 2010, 70, 1356-1366.	0.4	66
178	The molecular and cell biology of pediatric low-grade gliomas. Oncogene, 2014, 33, 2019-2026.	2.6	66
179	HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1. Molecular Psychiatry, 2015, 20, 1311-1321.	4.1	66
180	MicroRNA Profiling Reveals Marker of Motor Neuron Disease in ALS Models. Journal of Neuroscience, 2017, 37, 5574-5586.	1.7	66

#	Article	IF	Citations
181	Genetic and genomic alterations differentially dictate low-grade glioma growth through cancer stem cellâ€“specific chemokine recruitment of T cells and microglia. Neuro-Oncology, 2019, 21, 1250-1262.	0.6	66
182	Mutations in the GAP-related domain impair the ability of neurofibromin to associate with microtubules. Brain Research, 1997, 759, 149-152.	1.1	64
183	The Protein 4.1 Tumor Suppressor, DAL-1, Impairs Cell Motility, But Regulates Proliferation in a Cell-Type-Specific Fashion. Neurobiology of Disease, 2001, 8, 266-278.	2.1	64
184	Tumor suppressor Tsc1 is a new Hsp90 coâ€chaperone that facilitates folding of kinase and nonâ€kinase clients. EMBO Journal, 2017, 36, 3650-3665.	3.5	64
185	let-7 MicroRNAs Regulate Microglial Function and Suppress Glioma Growth through Toll-Like Receptor 7. Cell Reports, 2019, 29, 3460-3471.e7.	2.9	64
186	Highâ€fat diet ameliorates neurological deficits caused by defective astrocyte lipid metabolism. FASEB Journal, 2012, 26, 4302-4315.	0.2	63
187	Insights into Meningioangiomatosis with and without Meningioma: A Clinicopathologic and Genetic Series of 24 Cases with Review of the Literature. Brain Pathology, 2005, 15, 55-65.	2.1	62
188	Tumorigenesis in the Brain: Location, Location, Location: Figure 1.. Cancer Research, 2007, 67, 5579-5582.	0.4	62
189	Loss of Tumor Suppressor in Lung Cancer-1 (TSLC1) Expression in Meningioma Correlates with Increased Malignancy Grade and Reduced Patient Survival. Journal of Neuropathology and Experimental Neurology, 2004, 63, 1015-1027.	0.9	61
190	Nucleophosmin Mediates Mammalian Target of Rapamycinâ€“Dependent Actin Cytoskeleton Dynamics and Proliferation in Neurofibromin-Deficient Astrocytes. Cancer Research, 2007, 67, 4790-4799.	0.4	61
191	NF1germline mutation differentially dictates optic glioma formation and growth in neurofibromatosis-1. Human Molecular Genetics, 2016, 25, 1703-1713.	1.4	61
192	Neurodevelopmental disorders in children with neurofibromatosis type 1. Developmental Medicine and Child Neurology, 2017, 59, 1112-1116.	1.1	61
193	Recent Insights Into Neurofibromatosis TypeÂ1. Archives of Neurology, 1998, 55, 778.	4.9	60
194	miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells. Oncogene, 2013, 32, 4712-4720.	2.6	60
195	Expression of two new protein isoforms of the neurofibromatosis type 1 gene product, neurofibromin, in muscle tissues. Developmental Dynamics, 1995, 202, 302-311.	0.8	59
196	Developmental regulation of a neuron-specific neurofibromatosis 1 isoform. Annals of Neurology, 1999, 46, 777-782.	2.8	59
197	Suppression of MicroRNA-9 by Mutant EGFR Signaling Upregulates FOXP1 to Enhance Glioblastoma Tumorigenicity. Cancer Research, 2014, 74, 1429-1439.	0.4	59
198	Harnessing preclinical mouse models to inform human clinical cancer trials. Journal of Clinical Investigation, 2006, 116, 847-852.	3.9	59

#	Article	IF	Citations
199	Differential Involvement of Protein 4.1 Family Members DAL-1 and NF2 in Intracranial and Intraspinal Ependymomas. Modern Pathology, 2002, 15, 526-531.	2.9	58
200	Cerebrospinal Fluid Proteomic Analysis Reveals Dysregulation of Methionine Aminopeptidase-2 Expression in Human and Mouse Neurofibromatosis 1â€“Associated Glioma. Cancer Research, 2005, 65, 9843-9850.	0.4	58
201	The Natural History and Treatment of Epilepsy in a Murine Model of Tuberous Sclerosis. Epilepsia, 2007, 48, 1470-1476.	2.6	58
202	Attention Skills in Children With Neurofibromatosis Type 1. Journal of Child Neurology, 2013, 28, 45-49.	0.7	58
203	Neurofibromatosis 2 (NF2) tumor suppressor schwannomin and its interacting protein HRS regulate STAT signaling. Human Molecular Genetics, 2002, 11, 3179-3189.	1.4	57
204	A review of astrocytoma models. Neurosurgical Focus, 2000, 8, 1-8.	1.0	56
205	Mouse Models of Neurofibromatosis 1 and 2. Neoplasia, 2002, 4, 279-290.	2.3	56
206	MicroRNA profiling in pediatric pilocytic astrocytoma reveals biologically relevant targets, including PBX3, NFIB, and METAP2. Neuro-Oncology, 2013, 15, 69-82.	0.6	56
207	The Cyclic AMP Pathway Is a Sex-Specific Modifier of Glioma Risk in Type I Neurofibromatosis Patients. Cancer Research, 2015, 75, 16-21.	0.4	56
208	Oculodentodigital dysplasia syndrome associated with abnormal cerebral white matter. American Journal of Medical Genetics Part A, 1991, 41, 18-20.	2.4	55
209	Neurofibromatosis-1 heterozygosity impairs CNS neuronal morphology in a cAMP/PKA/ROCK-dependent manner. Molecular and Cellular Neurosciences, 2012, 49, 13-22.	1.0	55
210	The neurobiology of neurooncology. Annals of Neurology, 2006, 60, 3-11.	2.8	54
211	Pathological and Molecular Progression of Astrocytomas in a GFAP:12V-Ha-Ras Mouse Astrocytoma Model. American Journal of Pathology, 2005, 167, 859-867.	1.9	53
212	A multi-institutional study of brainstem gliomas in children with neurofibromatosis type 1. Neurology, 2017, 88, 1584-1589.	1.5	53
213	Developmental origin of subependymal giant cell astrocytoma in tuberous sclerosis complex. Neurology, 2005, 64, 1446-1449.	1.5	52
214	Gliomas in patients with neurofibromatosis type 1. Expert Review of Neurotherapeutics, 2009, 9, 535-539.	1.4	52
215	Recent progress toward understanding the molecular biology of von Recklinghausen neurofibromatosis. Annals of Neurology, 1992, 31, 555-561.	2.8	51
216	Loss of neurofibromatosis type I (NFI) gene expression in pheochromocytomas from patients without NFI. Genes Chromosomes and Cancer, 1995, 13, 104-109.	1.5	51

#	Article	IF	Citations
217	Neurofibromatosis 2 tumor suppressor protein, merlin, forms two functionally important intramolecular associations. , 1999, 58, 706-716.		51
218	Expression of the tuberous sclerosis complex gene products, hamartin and tuberin, in central nervous system tissues. Acta Neuropathologica, 2000, 99, 223-230.	3.9	51
219	Heterozygosity for the neurofibromatosis 1 (NF1) tumor suppressor results in abnormalities in cell attachment, spreading and motility in astrocytes. Human Molecular Genetics, 2001, 10, 3009-3016.	1.4	51
220	Merlin isoform 2 in neurofibromatosis type 2â€“associated polyneuropathy. Nature Neuroscience, 2013, 16, 426-433.	7.1	51
221	Prevalence of Sleep Disturbances in Children With Neurofibromatosis Type 1. Journal of Child Neurology, 2013, 28, 1400-1405.	0.7	51
222	Pediatric gliomas as neurodevelopmental disorders. Glia, 2016, 64, 879-895.	2.5	51
223	Functional analysis of neurofibromatosis 2 (NF2) missense mutations. Human Molecular Genetics, 2001, 10, 1519-1529.	1.4	49
224	Diffusion-weighted and dynamic contrast-enhanced imaging as markers of clinical behavior in children with optic pathway glioma. Pediatric Radiology, 2008, 38, 1293-1299.	1.1	49
225	Neurofibromin regulates somatic growth through the hypothalamicâ€“pituitary axis. Human Molecular Genetics, 2008, 17, 2956-2966.	1.4	49
226	Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1. Communications Biology, 2018, 1, 158.	2.0	49
227	Expression of a developmentally-regulated neuron-specific isoform of the neurofibromatosis 1 (NF1) gene. Neuroscience Letters, 1996, 211, 85-88.	1.0	48
228	The monolayer formation of Bergmann glial cells is regulated by Notch/RBP-J signaling. Developmental Biology, 2007, 311, 238-250.	0.9	48
229	Human iPSC-Derived Neurons and Cerebral Organoids Establish Differential Effects of Germline NF1 Gene Mutations. Stem Cell Reports, 2020, 14, 541-550.	2.3	48
230	Alterations in the rap1 signaling pathway are common in human gliomas. Oncogene, 1997, 15, 1611-1616.	2.6	47
231	Estrogen activation of microglia underlies the sexually dimorphic differences in Nf1 optic gliomaâ€“induced retinal pathology. Journal of Experimental Medicine, 2017, 214, 17-25.	4.2	46
232	Cabozantinib for neurofibromatosis type 1â€“related plexiform neurofibromas: a phase 2 trial. Nature Medicine, 2021, 27, 165-173.	15.2	46
233	Ccl5 establishes an autocrine high-grade glioma growth regulatory circuit critical for mesenchymal glioblastoma survival. Oncotarget, 2017, 8, 32977-32989.	0.8	46
234	Modulation of the neurofibromatosis type 1 gene product, neurofibromin, during Schwann cell differentiation. Journal of Neuroscience Research, 1993, 36, 216-223.	1.3	45

#	Article	IF	Citations
235	Expression of the neurofibromatosis 2 (NF2) gene isoforms during rat embryonic development. Human Molecular Genetics, 1995, 4, 471-478.	1.4	45
236	Expression profiling in tuberous sclerosis complex (TSC) knockout mouse astrocytes to characterize human TSC brain pathology. Glia, 2004, 46, 28-40.	2.5	45
237	Alterations of protein 4.1 family members in ependymomas: a study of 84 cases. Modern Pathology, 2005, 18, 991-997.	2.9	45
238	Optic Nerve Dysfunction in a Mouse Model of Neurofibromatosis-1 Optic Glioma. Journal of Neuropathology and Experimental Neurology, 2009, 68, 542-551.	0.9	45
239	Athymic mice reveal a requirement for T-cellâ€“microglia interactions in establishing a microenvironment supportive ofNf1low-grade glioma growth. Genes and Development, 2018, 32, 491-496.	2.7	45
240	A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1â€“associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. Neuro-Oncology, 2020, 22, 1527-1535.	0.6	45
241	RNAâ€sequencing reveals oligodendrocyte and neuronal transcripts in microglia relevant to central nervous system disease. Glia, 2015, 63, 531-548.	2.5	44
242	The mTOR signaling pathway as a treatment target for intracranial neoplasms. Neuro-Oncology, 2015, 17, 189-199.	0.6	44
243	Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. Neuro-Oncology, 2020, 22, 773-784.	0.6	44
244	The NF2 interactor, hepatocyte growth factor-regulated tyrosine kinase substrate (HRS), associates with merlin in the 'open' conformation and suppresses cell growth and motility. Human Molecular Genetics, 2001, 10, 825-834.	1.4	43
245	Gene Expression Profiling of NF-1-Associated and Sporadic Pilocytic Astrocytoma Identifies Aldehyde Dehydrogenase 1 Family Member L1 (ALDH1L1) as an Underexpressed Candidate Biomarker in Aggressive Subtypes. Journal of Neuropathology and Experimental Neurology, 2008, 67, 1194-1204.	0.9	43
246	How Support of Early Career Researchers Can Reset Science in the Post-COVID19 World. Cell, 2020, 181, 1445-1449.	13.5	43
247	Humanized neurofibroma model from induced pluripotent stem cells delineates tumor pathogenesis and developmental origins. Journal of Clinical Investigation, 2021, 131, .	3.9	43
248	Transcriptional Repression of the Neurofibromatosis-1 Tumor Suppressor by the t(8;21) Fusion Protein. Molecular and Cellular Biology, 2005, 25, 5869-5879.	1.1	42
249	A Conserved Circadian Function for the Neurofibromatosis 1 Gene. Cell Reports, 2018, 22, 3416-3426.	2.9	42
250	Loss of TDP-43 in astrocytes leads to motor deficits by triggering A1-like reactive phenotype and triglial dysfunction. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 29101-29112.	3.3	42
251	Oculodentodigital dysplasia with cerebral white matter abnormalities in a two-generation family. American Journal of Medical Genetics Part A, 1995, 57, 458-461.	2.4	41
252	Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft. International Journal of Cancer, 2010, 126, 563-571.	2.3	41

#	Article	IF	Citations
253	Identification of Gene Markers Associated With Aggressive Meningioma by Filtering Across Multiple Sets of Gene Expression Arrays. Journal of Neuropathology and Experimental Neurology, 2011, 70, 1-12.	0.9	40
254	F11R Is a Novel Monocyte Prognostic Biomarker for Malignant Glioma. PLoS ONE, 2013, 8, e77571.	1.1	40
255	cDNA Hybrid Capture Improves Transcriptome Analysis on Low-Input and Archived Samples. Journal of Molecular Diagnostics, 2014, 16, 440-451.	1.2	40
256	Neurofibromatosis-1 regulation of neural stem cell proliferation and multilineage differentiation operates through distinct RAS effector pathways. Genes and Development, 2015, 29, 1677-1682.	2.7	40
257	ReducedTSC2 RNA and protein in sporadic astrocytomas and ependymomas. Annals of Neurology, 1997, 42, 230-235.	2.8	39
258	Evaluation of participant recruitment methods to a rare disease online registry. American Journal of Medical Genetics, Part A, 2014, 164, 1686-1694.	0.7	39
259	Whole Exome Sequencing Reveals the Order of Genetic Changes during Malignant Transformation and Metastasis in a Single Patient with NF1-plexiform Neurofibroma. Clinical Cancer Research, 2015, 21, 4201-4211.	3.2	39
260	Mouse Low-Grade Gliomas Contain Cancer Stem Cells with Unique Molecular and Functional Properties. Cell Reports, 2015, 10, 1899-1912.	2.9	39
261	Dissecting Clinical Heterogeneity in Neurofibromatosis Type 1. Annual Review of Pathology: Mechanisms of Disease, 2017, 12, 53-74.	9.6	39
262	Molecular Insights into Neurofibromatosis 2. Neurobiology of Disease, 1997, 3, 247-261.	2.1	38
263	Differential Cellular Expression of Neurotrophins in Cortical Tubers of the Tuberous Sclerosis Complex. American Journal of Pathology, 2001, 159, 1541-1554.	1.9	38
264	Merlin: hanging tumor suppression on the Rac. Trends in Cell Biology, 2001, 11, 442-444.	3.6	38
265	Gender as a disease modifier in neurofibromatosis type 1 optic pathway glioma. Annals of Neurology, 2014, 75, 799-800.	2.8	38
266	Hereditary retinal vasculopathy with cerebral white matter lesions. American Journal of Medical Genetics Part A, 1989, 34, 217-220.	2.4	37
267	The Generation and Characterization of a Cell Line Derived from a Sporadic Renal Angiomyolipoma. American Journal of Pathology, 2001, 159, 483-491.	1.9	37
268	The 4.1/ezrin/radixin/moesin domain of the DAL-1/Protein 4.1B tumour suppressor interacts with 14-3-3 proteins. Biochemical Journal, 2002, 365, 783-789.	1.7	37
269	CD44-independent hepatocyte growth factor/c-Met autocrine loop promotes malignant peripheral nerve sheath tumor cell invasion in vitro. Glia, 2004, 45, 297-306.	2.5	36
270	TSC1 Sets the Rate of Ribosome Export and Protein Synthesis through Nucleophosmin Translation. Cancer Research, 2007, 67, 1609-1617.	0.4	36

#	Article	IF	Citations
271	Glomus tumors in individuals with neurofibromatosis type 1. Journal of the American Academy of Dermatology, 2014, 71, 44-48.	0.6	36
272	Proteomic analysis reveals GIT1 as a novel mTOR complex component critical for mediating astrocyte survival. Genes and Development, 2016, 30, 1383-1388.	2.7	36
273	Tenascin C regulates multiple microglial functions involving TLR4 signaling and HDAC1. Brain, Behavior, and Immunity, 2019, 81, 470-483.	2.0	36
274	Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1). Acta Neuropathologica, 2021, 141, 605-617.	3.9	36
275	Overexpression of bax in human glioma cell lines. Journal of Neurosurgery, 1999, 91, 483-489.	0.9	35
276	Functional significance of S6K overexpression in meningioma progression. Annals of Neurology, 2004, 56, 295-298.	2.8	35
277	PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice. Experimental Neurology, 2011, 232, 333-338.	2.0	35
278	BRAFV600E mutation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. Neuro-Oncology, 2014, 16, 466-467.	0.6	35
279	Juvenile xanthogranuloma, neurofibromatosis 1, and juvenile chronic myeloid leukemia. Archives of Dermatology, 1996, 132, 1390-1391.	1.7	35
280	Ku80 functions as a tumor suppressor in hepatocellular carcinoma by inducing S-phase arrest through a p53-dependent pathway. Carcinogenesis, 2012, 33, 538-547.	1.3	34
281	Junctional Adhesion Molecules in Cancer: A Paradigm for the Diverse Functions of Cellâ€“Cell Interactions in Tumor Progression. Cancer Research, 2020, 80, 4878-4885.	0.4	34
282	Expression of the Tuberous Sclerosis 2 Gene Product, Tuberin, in Adult and Developing Nervous System Tissues. Neurobiology of Disease, 1996, 3, 111-120.	2.1	33
283	Acute presentation of a neurogenic sarcoma in a patient with neurofibromatosis type 1: a pathological and molecular explanation. Journal of Neurosurgery, 1996, 84, 867-873.	0.9	33
284	Advances in Neurofibromatosis 2 (NF2): A Workshop Report. Journal of Neurogenetics, 2000, 14, 63-106.	0.6	33
285	Comparative Characterization of the Human and Mouse Third Ventricle Germinal Zones. Journal of Neuropathology and Experimental Neurology, 2011, 70, 622-633.	0.9	33
286	Protein 4.1B/Differentially Expressed in Adenocarcinoma of the Lung-1 Functions as a Growth Suppressor in Meningioma Cells by Activating Rac1-Dependent c-Jun-NH2-kinase Signaling. Cancer Research, 2006, 66, 5295-5303.	0.4	32
287	Interpreting Mammalian Target of Rapamycin and Cell Growth Inhibition in a Genetically Engineered Mouse Model of Nf1-Deficient Astrocytes. Molecular Cancer Therapeutics, 2011, 10, 279-291.	1.9	32
288	Characterization of early communicative behavior in mouse models of neurofibromatosis type 1. Autism Research, 2018, 11, 44-58.	2.1	32

#	Article	IF	Citations
289	Cognition, ADHD Symptoms, and Functional Impairment in Children and Adolescents With Neurofibromatosis Type 1. Journal of Attention Disorders, 2021, 25, 1177-1186.	1.5	32
290	Loss of heterozygosity for theNF2gene in retinal and optic nerve lesions of patients with neurofibromatosis 2. Journal of Pathology, 2002, 198, 14-20.	2.1	31
291	Tslc1 (Nectin-Like Molecule-2) Is Essential for Spermatozoa Motility and Male Fertility. Journal of Andrology, 2006, 27, 816-825.	2.0	31
292	Expression profiling identifies a molecular signature of reactive astrocytes stimulated by cyclic AMP or proinflammatory cytokines. Experimental Neurology, 2008, 210, 261-267.	2.0	31
293	Developmental Delays in Children With Neurofibromatosis Type 1. Journal of Child Neurology, 2012, 27, 641-644.	0.7	31
294	Neurofibromatosis 2. Current Opinion in Neurology, 2003, 16, 27-33.	1.8	31
295	Neurofibromatosis Type 1. Archives of Neurology, 1993, 50, 1185.	4.9	30
296	Meningothelial Hyperplasia: A Detailed Clinicopathologic, Immunohistochemical and Genetic Study of 11 Cases. Brain Pathology, 2006, 15, 109-115.	2.1	30
297	Using Neurofibromatosis-1 to Better Understand and Treat Pediatric Low-Grade Glioma. Journal of Child Neurology, 2008, 23, 1186-1194.	0.7	30
298	Fatty acid synthase as a novel target for meningioma therapy. Neuro-Oncology, 2010, 12, 844-854.	0.6	30
299	Postoperative imaging surveillance in pediatric pilocytic astrocytomas. Journal of Neurosurgery: Pediatrics, 2010, 6, 346-352.	0.8	30
300	Development of an international internet-based neurofibromatosis Type 1 Patient registry. Contemporary Clinical Trials, 2013, 34, 305-311.	0.8	30
301	Assessment of Pain and Itch Behavior in a Mouse Model ofÂNeurofibromatosis Type 1. Journal of Pain, 2013, 14, 628-637.	0.7	30
302	Antiangiogenic Agents for Nonmalignant Brain Tumors. Journal of Neurological Surgery, Part B: Skull Base, 2013, 74, 136-141.	0.4	30
303	Spatially- and temporally-controlled postnatal p53 knockdown cooperates with embryonic Schwann cell precursor Nf1 gene loss to promote malignant peripheral nerve sheath tumor formation. Oncotarget, 2016, 7, 7403-7414.	0.8	30
304	Functional analysis of the relationship between the neurofibromatosis 2 tumor suppressor and its binding partner, hepatocyte growth factor-regulated tyrosine kinase substrate. Human Molecular Genetics, 2002, 11, 3167-3178.	1.4	29
305	Reduced Activity of CD13/Aminopeptidase N (APN) in Aggressive Meningiomas Is Associated with Increased Levels of SPARC. Brain Pathology, 2010, 20, 200-210.	2.1	29
306	The Learning Disabilities Network (LeaDNet): Using neurofibromatosis type 1 (NF1) as a paradigm for translational research. American Journal of Medical Genetics, Part A, 2012, 158A, 2225-2232.	0.7	29

#	Article	IF	Citations
307	Height Assessments in Children With Neurofibromatosis Type 1. Journal of Child Neurology, 2013, 28, 303-307.	0.7	29
308	Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1. Nature Communications, 2022, 13, 2785.	5.8	29
309	Aberrant G protein signaling in nervous system tumors. Journal of Neurosurgery, 2002, 97, 627-642.	0.9	28
310	Ultrastructural characterization of the optic pathway in a mouse model of neurofibromatosis-1 optic glioma. Neuroscience, 2010, 170, 178-188.	1.1	28
311	A Novel Rac1-GSPT1 Signaling Pathway Controls Astrogliosis Following Central Nervous System Injury. Journal of Biological Chemistry, 2017, 292, 1240-1250.	1.6	28
312	KIAA1549-BRAF Expression Establishes a Permissive Tumor Microenvironment Through NFÎºB-Mediated CCL2 Production. Neoplasia, 2019, 21, 52-60.	2.3	28
313	Patient-derived iPSC-cerebral organoid modeling of the 17q11.2 microdeletion syndrome establishes CRLF3 as a critical regulator of neurogenesis. Cell Reports, 2021, 36, 109315.	2.9	28
314	Membrane localization of the U2 domain of Protein 4.1B is necessary and sufficient for meningioma growth suppression. Oncogene, 2005, 24, 1946-1957.	2.6	27
315	Akt-Dependent Cell Size Regulation by the Adhesion Molecule on Glia Occurs Independently of Phosphatidylinositol 3-Kinase and Rheb Signaling. Molecular and Cellular Biology, 2005, 25, 3151-3162.	1.1	27
316	Regulation of mixed lineage kinase 3 is required for Neurofibromatosis-2-mediated growth suppression in human cancer. Oncogene, 2011, 30, 781-789.	2.6	27
317	Cognitive and behavioral problems in children with neurofibromatosis type 1: challenges and future directions. Expert Review of Neurotherapeutics, 2014, 14, 1139-1152.	1.4	27
318	Racial/Ethnic Differences in Pediatric Brain Tumor Diagnoses in Patients with Neurofibromatosis Type 1. Journal of Pediatrics, 2015, 167, 613-620.e2.	0.9	27
319	Neurofibromatosis type 1 and optic pathway glioma: Molecular interplay and therapeutic insights. Pediatric Blood and Cancer, 2018, 65, e26838.	0.8	27
320	Detection and measurement of neurofibromatosis-1 mouse optic glioma in vivo. NeuroImage, 2007, 35, 1434-1437.	2.1	26
321	Complicated hereditary spastic paraparesis with cerebral white matter lesions. American Journal of Medical Genetics Part A, 1990, 36, 251-257.	2.4	25
322	Merlin: hanging tumor suppression on the Rac. Trends in Cell Biology, 2001, 11, 442-444.	3.6	25
323	Optic nerve tortuosity in children with neurofibromatosis type 1. Pediatric Radiology, 2013, 43, 1336-1343.	1.1	25
324	NG2-cells are not the cell of origin for murine neurofibromatosis-1 (Nf1) optic glioma. Oncogene, 2014, 33, 289-299.	2.6	25

#	Article	IF	Citations
325	Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1â€associated malignant peripheral nerve sheath tumors. Cancer, 2017, 123, 1194-1201.	2.0	25
326	Glioneuronal tumours in neurofibromatosis type 1: MRI-pathological study. Journal of Clinical Neuroscience, 2004, 11, 745-747.	0.8	24
327	Longitudinal Analysis of Developmental Delays in Children With Neurofibromatosis Type 1. Journal of Child Neurology, 2013, 28, 1689-1693.	0.7	24
328	Children with 5â€²-end NF1 gene mutations are more likely to have glioma. Neurology: Genetics, 2017, 3, e192.	0.9	24
329	Postnatal reduction of tuberous sclerosis complex 1 expression in astrocytes and neurons causes seizures in an ageâ€dependent manner. Epilepsia, 2017, 58, 2053-2063.	2.6	24
330	Reproducibility of cognitive endpoints in clinical trials: lessons from neurofibromatosis type 1. Annals of Clinical and Translational Neurology, 2019, 6, 2555-2565.	1.7	24
331	The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation. Oncotarget, 2017, 8, 47206-47215.	0.8	24
332	Expression of the neurofibromatosis 1 (NF1) gene in reactive astrocytes in vitro. NeuroReport, 1995, 6, 1565-1568.	0.6	23
333	Chapter 33 Expression of the neurofibromatosis type 1 (NF1) gene during mouse embryonic development. Progress in Brain Research, 1995, 105, 327-335.	0.9	23
334	Mlh1 deficiency accelerates myeloid leukemogenesis in neurofibromatosis 1 (Nf1) heterozygous mice. Oncogene, 2003, 22, 4581-4585.	2.6	23
335	Mouse Models of Tuberous Sclerosis Complex. Journal of Child Neurology, 2004, 19, 726-733.	0.7	23
336	Expression and Function of Somatostatin Receptors in Peripheral Nerve Sheath Tumors. Journal of Neuropathology and Experimental Neurology, 2005, 64, 1080-1088.	0.9	23
337	Activated K-Ras, but Not H-Ras or N-Ras, Regulates Brain Neural Stem Cell Proliferation in a Raf/Rb-Dependent Manner. Stem Cells, 2015, 33, 1998-2010.	1.4	23
338	Neurofibromatosis type 1 and chronic neurological conditions in the United States: an administrative claims analysis. Genetics in Medicine, 2015, 17, 36-42.	1.1	23
339	Distribution and Within-Family Specificity of Quantitative Autistic Traits inÂPatients with Neurofibromatosis Type I. Journal of Pediatrics, 2015, 167, 621-626.e1.	0.9	23
340	Mice with missense and nonsense NF1 mutations display divergent phenotypes compared to NF1 patients. DMM Disease Models and Mechanisms, 2016, 9, 759-67.	1.2	23
341	Increased prevalence of brain tumors classified as T2 hyperintensities in neurofibromatosis 1. Neurology: Clinical Practice, 2018, 8, 283-291.	0.8	23
342	Brain tumors in neurofibromatosis type 1. Neuro-Oncology Advances, 2020, 2, i85-i97.	0.4	23

#	Article	IF	Citations
343	Review Article : Neurofibromin in the Brain. Journal of Child Neurology, 2002, 17, 592-601.	0.7	22
344	Astrocyte-specific expression of CDK4 is not sufficient for tumor formation, but cooperates with p53 heterozygosity to provide a growth advantage for astrocytes in vivo. Oncogene, 2002, 21, 1325-1334.	2.6	22
345	Role of the Rap1 GTPase in astrocyte growth regulation. Glia, 2003, 42, 225-234.	2.5	22
346	Expression of the Tumor Suppressor Genes NF2, 4.1B, and TSLC1 in Canine Meningiomas. Veterinary Pathology, 2009, 46, 884-892.	0.8	22
347	Learning Disabilities in Neurofibromatosis 1. Archives of Neurology, 1999, 56, 1322.	4.9	21
348	Molecular analysis of malignant triton tumors. Human Pathology, 1999, 30, 984-988.	1.1	21
349	Mouse glioma gene expression profiling identifies novel human glioma-associated genes. Annals of Neurology, 2002, 51, 393-405.	2.8	21
350	HRS inhibits EGF receptor signaling in the RT4 rat schwannoma cell line. Biochemical and Biophysical Research Communications, 2005, 335, 385-392.	1.0	21
351	Brainstem Glioma Presenting as Pruritus in Children With Neurofibromatosis-1. Journal of Pediatric Hematology/Oncology, 2009, 31, 972-976.	0.3	21
352	Motivational Disturbances and Effects of L-dopa Administration in Neurofibromatosis-1 Model Mice. PLoS ONE, 2013, 8, e66024.	1.1	21
353	Defining the temporal course of murine neurofibromatosis-1 optic gliomagenesis reveals a therapeutic window to attenuate retinal dysfunction. Neuro-Oncology, 2017, 19, now267.	0.6	21
354	Updated nomenclature for human and mouse neurofibromatosis type 1 genes. Neurology: Genetics, 2017, 3, e169.	0.9	21
355	Whole tumor RNA-sequencing and deconvolution reveal a clinically-prognostic PTEN/PI3K-regulated glioma transcriptional signature. Oncotarget, 2017, 8, 52474-52487.	0.8	21
356	Neurofibromatosis 2 tumor suppressor protein, merlin, forms two functionally important intramolecular associations. Journal of Neuroscience Research, 1999, 58, 706-16.	1.3	21
357	Asthma reduces glioma formation by T cell decorin-mediated inhibition of microglia. Nature Communications, 2021, 12, 7122.	5.8	21
358	Molecular biology of duchenne and Becker's muscular dystrophy: Clinical applications. Annals of Neurology, 1989, 26, 189-194.	2.8	20
359	NovelBRAFAlteration in a Sporadic Pilocytic Astrocytoma. Case Reports in Medicine, 2012, 2012, 1-4.	0.3	20
360	A genotypeâ€“phenotype correlation for quantitative autistic trait burden in neurofibromatosis 1. Neurology, 2018, 90, 377-379.	1.5	20

#	Article	IF	Citations
361	Human stem cell modeling in neurofibromatosis type 1 (NF1). Experimental Neurology, 2018, 299, 270-280.	2.0	20
362	Ammonium Acetate Protocol for the Preparation of Plasmid DNA Suitable for Mammalian Cell Transfections. BioTechniques, 1997, 23, 424-427.	0.8	19
363	Protein 4.1B expression is induced in mammary epithelial cells during pregnancy and regulates their proliferation. Oncogene, 2005, 24, 6502-6515.	2.6	19
364	Increased Tissue Stiffness in Tumors from Mice with Neurofibromatosis-1 Optic Glioma. Biophysical Journal, 2017, 112, 1535-1538.	0.2	19
365	Reimagining pilocytic astrocytomas in the context of pediatric low-grade gliomas. Neuro-Oncology, 2021, 23, 1634-1646.	0.6	19
366	Characterization and expression of H-2I region gene products on bone marrow-derived macrophages. European Journal of Immunology, 1982, 12, 991-997.	1.6	18
367	Colocalized cellular schwannoma and plexiform neurofibroma in the absence of neurofibromatosis. Journal of Neurosurgery, 2007, 107, 435-439.	0.9	18
368	The ecology of brain tumors: lessons learned from neurofibromatosis-1. Oncogene, 2011, 30, 1135-1146.	2.6	18
369	Identification of transcriptional regulatory networks specific to pilocytic astrocytoma. BMC Medical Genomics, 2011, 4, 57.	0.7	18
370	The impact of coexisting genetic mutations on murine optic glioma biology. Neuro-Oncology, 2015, 17, 670-677.	0.6	18
371	Clearing the Fog surrounding Chemobrain. Cell, 2019, 176, 2-4.	13.5	18
372	ABCG1 maintains high-grade glioma survival in vitro and in vivo. Oncotarget, 2016, 7, 23416-23424.	0.8	18
373	T lymphocytes as dynamic regulators of glioma pathobiology. Neuro-Oncology, 2022, 24, 1647-1657.	0.6	18
374	Disruption of 14-3-3 binding does not impair Protein 4.1B growth suppression. Oncogene, 2004, 23, 3589-3596.	2.6	17
375	Update from the 2013 international neurofibromatosis conference. American Journal of Medical Genetics, Part A, 2014, 164, 2969-2978.	0.7	17
376	Microglia in the tumor microenvironment: taking their TOLL on glioma biology. Neuro-Oncology, 2015, 17, 171-173.	0.6	17
377	3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma. Journal of Proteomics, 2016, 149, 77-84.	1.2	17
378	Adaptive functioning in children with neurofibromatosis type 1: relationship to cognition, behavior, and magnetic resonance imaging. Developmental Medicine and Child Neurology, 2019, 61, 972-978.	1.1	17

#	Article	IF	Citations
379	Variability of Betweenness Centrality and Its Effect on Identifying Essential Genes. Bulletin of Mathematical Biology, 2019, 81, 3655-3673.	0.9	17
380	RNA sequence analysis reveals ITGAL/CD11A as a stromal regulator of murine low-grade glioma growth. Neuro-Oncology, 2022, 24, 14-26.	0.6	17
381	New insights into the neurofibromatoses. Current Opinion in Neurology, 1994, 7, 166-171.	1.8	16
382	A Neuropsychological Perspective on Attention Problems in Neurofibromatosis Type 1. Journal of Attention Disorders, 2013, 17, 489-496.	1.5	16
383	Conditional KIAA1549:BRAF mice reveal brain regionâ€•and cell typeâ€specific effects. Genesis, 2013, 51, 708-716.	0.8	16
384	Parallels between tuberous sclerosis complex and neurofibromatosis 1: Common threads in the same tapestry. Seminars in Pediatric Neurology, 1998, 5, 276-286.	1.0	15
385	Transfection of C6 glioma cells with the bax gene and increased sensitivity to treatment with cytosine arabinoside. Journal of Neurosurgery, 1998, 88, 99-105.	0.9	15
386	Eliminating barriers to personalized medicine. Neurology, 2014, 83, 463-471.	1.5	15
387	Validity of participant-reported diagnoses in an online patient registry: A report from the NF1 Patient Registry Initiative. Contemporary Clinical Trials, 2015, 40, 212-217.	0.8	15
388	Neurofibromatosis 2 in children presenting during the first decade of life. Neurology, 2019, 93, e964-e967.	1.5	15
389	Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1. Journal of Neuroscience Research, 2019, 97, 45-56.	1.3	15
390	Nonoptic pathway tumors in children with neurofibromatosis type 1. Neurology, 2020, 95, e1052-e1059.	1.5	15
391	BRAF mutations may identify a clinically distinct subset of glioblastoma. Scientific Reports, 2021, 11, 19999.	1.6	15
392	Genetic heterogeneity of stably transfected cell lines revealed by expression profiling with oligonucleotide microarrays. Journal of Cellular Biochemistry, 2003, 90, 1068-1078.	1.2	14
393	Cancer stem cells and brain tumors: uprooting the bad seeds. Expert Review of Anticancer Therapy, 2007, 7, 1581-1590.	1.1	14
394	Defining future directions in spinal cord tumor research. Journal of Neurosurgery: Spine, 2010, 12, 117-121.	0.9	14
395	Magnetic resonance imaging of ataxic hemiparesis localized to the corona radiata.. Stroke, 1989, 20, 1571-1573.	1.0	13
396	Cerebral vasculopathy and infarction in a woman with carcinomatous meningitis. Journal of Neuro-Oncology, 1990, 9, 183-185.	1.4	13

#	Article	IF	Citations
397	Comments on neurofibromatosis 1 and optic pathway tumors. American Journal of Medical Genetics Part A, 2001, 102, 105-105.	2.4	13
398	CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. Journal of Neuroimmunology, 2010, 224, 108-113.	1.1	13
399	Nf2/Merlin Controls Spinal Cord Neural Progenitor Function in a Rac1/ErbB2-Dependent Manner. PLoS ONE, 2014, 9, e97320.	1.1	13
400	Improving outcomes for neurofibromatosis 1â€“associated brain tumors. Expert Review of Anticancer Therapy, 2015, 15, 415-423.	1.1	13
401	Parental age and Neurofibromatosis Type 1: a report from the NF1 Patient Registry Initiative. Familial Cancer, 2015, 14, 317-324.	0.9	13
402	Pain symptomology, functional impact, and treatment of people with Neurofibromatosis type 1 . Journal of Pain Research, 2019, Volume 12, 2555-2561.	0.8	13
403	Lack ofNF1 expression in a sporadic schwannoma from a patient without neurofibromatosis. Journal of Neuro-Oncology, 1995, 25, 103-111.	1.4	12
404	Piebaldism and Neurofibromatosis Type 1: Horses of Very Different Colors. Journal of Investigative Dermatology, 2004, 122, xxxiv-xxxv.	0.3	12
405	Commentary: Identification of Mutation Regions on NF1 Responsible for High- and Low-Risk Development of Optic Pathway Glioma in Neurofibromatosis Type I. Frontiers in Genetics, 2019, 10, 115.	1.1	12
406	Transglutaminase 2 Expression Is Increased as a Function of Malignancy Grade and Negatively Regulates Cell Growth in Meningioma. PLoS ONE, 2014, 9, e108228.	1.1	12
407	Associations between allergic conditions and pediatric brain tumors in Neurofibromatosis type 1. Familial Cancer, 2016, 15, 301-308.	0.9	11
408	NF1 glioblastoma clonal profiling reveals KMT2B mutations as potential somatic oncogenic events. Neurology, 2019, 93, 1067-1069.	1.5	11
409	Neurofibromatosis type 1 (Nf1)â€mutant mice exhibit increased sleep fragmentation. Journal of Sleep Research, 2019, 28, e12816.	1.7	11
410	RAS and beyond: the many faces of the neurofibromatosis type 1 protein. DMM Disease Models and Mechanisms, 2022, 15, .	1.2	11
411	IN-VITRO-DERIVED BONE MARROW MACROPHAGES. Transplantation, 1984, 37, 585-589.	0.5	10
412	Expression of the neurofibromatosis 1 (NF1) gene during growth arrest. NeuroReport, 1996, 7, 601-604.	0.6	10
413	Diethylstilbestrol effects and lymphomagenesis in Mlh1 â€deficient mice. International Journal of Cancer, 2005, 115, 666-669.	2.3	10
414	Challenges in Drug Discovery for Neurofibromatosis Type 1-Associated Low-Grade Glioma. Frontiers in Oncology, 2016, 6, 259.	1.3	10

#	Article	IF	Citations
415	Neurofibromatosis 1 - Mutant microglia exhibit sexually-dimorphic cyclic AMP-dependent purinergic defects. Neurobiology of Disease, 2020, 144, 105030.	2.1	10
416	Symptomatic hydrocephalus and reversible spinal cord compression in Listeria monocytogenes meningitis. Journal of Neurosurgery, 1989, 71, 620-622.	0.9	9
417	Congenital nystagmus in a (46, XX/45,X) mosaic woman from a family with X-linked congenital nystagmus. American Journal of Medical Genetics Part A, 1991, 39, 167-169.	2.4	9
418	Chromosome 11q23.3-qter deletion and Alexander disease. American Journal of Medical Genetics Part A, 1991, 39, 226-226.	2.4	9
419	All in the family: Using inherited cancer syndromes to understand deâ€regulated cell signaling in brain tumors. Journal of Cellular Biochemistry, 2007, 102, 811-819.	1.2	9
420	Visual Function and Optic Pathway Glioma: A Critical Response. JAMA Ophthalmology, 2013, 131, 120.	1.4	9
421	Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1â€associated optic pathway gliomas in children. Pediatric Blood and Cancer, 2021, 68, e28833.	0.8	9
422	Neurofibroma and Cellular Neurofibroma with Atypia: A report of 14 tumors. American Journal of Surgical Pathology, 1999, 23, 1156.	2.1	9
423	Risk factors for treatment-refractory and relapsed optic pathway glioma in children with neurofibromatosis type 1. Neuro-Oncology, 2022, 24, 1377-1386.	0.6	9
424	The 43000 growth-associated protein functions as a negative growth regulator in glioma. Cancer Research, 2003, 63, 2933-9.	0.4	9
425	Generation of a reporter mouse line expressing Akt and EGFP upon Creâ€mediated recombination. Genesis, 2008, 46, 256-264.	0.8	8
426	Reply. Annals of Neurology, 2014, 75, 800-801.	2.8	8
427	The power of the few. Genes and Development, 2017, 31, 1177-1179.	2.7	8
428	Î²â€“III-spectrin immunohistochemistry as a potential diagnostic tool with high sensitivity for malignant peripheral nerve sheath tumors. Neuro-Oncology, 2018, 20, 858-860.	0.6	8
429	KIR2DL5 mutation and loss underlies sporadic dermal neurofibroma pathogenesis and growth. Oncotarget, 2017, 8, 47574-47585.	0.8	8
430	Personality changes associated with thalamic infiltration. Journal of Neuro-Oncology, 1990, 8, 263-7.	1.4	7
431	An alternative apnea test for the evaluation of brain death. Annals of Neurology, 1991, 30, 852-853.	2.8	7
432	Tumor Suppressor Gene Regulation of Cell Growth: Recent Insights into Neurofibromatosis 1 and 2 Gene Function. Cell Biochemistry and Biophysics, 2001, 34, 61-78.	0.9	7

#	Article	IF	Citations
433	Report from the Fifth National Cancer Institute Mouse Models of Human Cancers Consortium Nervous System Tumors Workshop. Neuro-Oncology, 2011, 13, 692-699.	0.6	7
434	Parent-of-origin in individuals with familial neurofibromatosis type 1 and optic pathway gliomas. Familial Cancer, 2012, 11, 653-656.	0.9	7
435	A Pilot Study for Evaluation of Hypotonia in Children With Neurofibromatosis Type 1. Journal of Child Neurology, 2015, 30, 382-385.	0.7	7
436	Contextual signaling in cancer. Seminars in Cell and Developmental Biology, 2016, 58, 118-126.	2.3	7
437	The management of neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors: challenges, progress, and future prospects. Expert Opinion on Orphan Drugs, 2017, 5, 623-631.	0.5	7
438	Temporal, spatial, and genetic constraints contribute to the patterning and penetrance of murine neurofibromatosis-1 optic glioma. Neuro-Oncology, 2021, 23, 625-637.	0.6	7
439	Visual field outcomes in children treated for neurofibromatosis type 1â€“associated optic pathway gliomas: a multicenter retrospective study. Journal of AAPOS, 2020, 24, 349.e1-349.e5.	0.2	7
440	Lipid composition and in vitro biosynthetic rates of neutral lipids and phosphatidylcholine in anterior and posterior chambers of the goldfish swimbladder. Comparative Biochemistry and Physiology A, Comparative Physiology, 1981, 69, 291-295.	0.7	6
441	Pseudocervical Cord Syndrome: A Deceptive Flumazenil Reversible Manifestation of Hepatic Encephalopathy. Archives of Neurology, 1996, 53, 956-956.	4.9	6
442	Reduced T-cadherin expression and promoter methylation are associated with the development and progression of hepatocellular carcinoma. International Journal of Oncology, 2008, , .	1.4	6
443	In Vivo Functional Analysis of the Human NF2 Tumor Suppressor Gene in Drosophila. PLoS ONE, 2014, 9, e90853.	1.1	6
444	Peri-gestational risk factors for pediatric brain tumors in Neurofibromatosis Type 1. Cancer Epidemiology, 2016, 42, 53-59.	0.8	6
445	The Tropism of Pleiotrophin: Orchestrating Glioma Brain Invasion. Cell, 2017, 170, 821-822.	13.5	6
446	Height Growth Impairment in Children With Neurofibromatosis Type 1 Is Characterized by Decreased Pubertal Growth Velocity in Both Sexes. Journal of Child Neurology, 2018, 33, 762-766.	0.7	6
447	Predictive Modeling for Clinical Features Associated With Neurofibromatosis Type 1. Neurology: Clinical Practice, 2021, 11, 497-505.	0.8	6
448	SRF Is Required for Maintenance of Astrocytes in Non-Reactive State in the Mammalian Brain. ENeuro, 2021, 8, ENEURO.0447-19.2020.	0.9	6
449	Rap1 activity is elevated in malignant astrocytomas independent of tuberous sclerosis complex-2 gene expression. International Journal of Oncology, 2003, 22, 195.	1.4	5
450	Genome-wide polymorphism analysis demonstrates a monoclonal origin of pilocytic astrocytoma. Neuropathology and Applied Neurobiology, 2011, 37, 321-325.	1.8	5

#	Article	IF	Citations
451	Rethinking Pediatric Gliomas as Developmental Brain Abnormalities. Current Topics in Developmental Biology, 2011, 94, 283-308.	1.0	5
452	The Association Between Hypotonia and Brain Tumors in Children With Neurofibromatosis Type 1. Journal of Child Neurology, 2013, 28, 1664-1667.	0.7	5
453	Gliosarcomas lack BRAF^{V600E} mutation, but a subset exhibit Î²â€catenin nuclear localization. Neuropathology, 2016, 36, 448-455.	0.7	5
454	Macrocephaly Is Not a Predictor of Optic Pathway Glioma Development or Treatment in Neurofibromatosis Type 1. Journal of Child Neurology, 2016, 31, 1540-1545.	0.7	5
455	Using Epigenetic Reprogramming to Treat Pediatric Brain Cancer. Cancer Cell, 2017, 31, 609-611.	7.7	5
456	Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma. PLoS ONE, 2018, 13, e0190001.	1.1	5
457	Shared developmental gait disruptions across two mouse models of neurodevelopmental disorders. Journal of Neurodevelopmental Disorders, 2021, 13, 10.	1.5	5
458	Immune deconvolution and temporal mapping identifies stromal targets and developmental intervals for abrogating murine low-grade optic glioma formation. Neuro-Oncology Advances, 2022, 4, vdab194.	0.4	5
459	Lowâ€grade gliomas as neurodevelopmental disorders: insights from mouse models of neurofibromatosisâ€1. Neuropathology and Applied Neurobiology, 2012, 38, 241-253.	1.8	4
460	Defining the Research Landscape for Dermal Neurofibromas. Oncology Times, 2016, 38, 14-15.	0.1	4
461	The Sociobiology of Brain Tumors. Advances in Experimental Medicine and Biology, 2020, 1225, 115-125.	0.8	4
462	Autism in neurofibromatosis type 1: misuse of covariance to dismiss autistic trait burden. Developmental Medicine and Child Neurology, 2021, 63, 233-234.	1.1	4
463	The Psychoimmune System in Later Life. , 1998, , 281-295.		4
464	Generation of human induced pluripotent stem cell-derived cerebral organoids for cellular and molecular characterization. STAR Protocols, 2022, 3, 101173.	0.5	4
465	Major histocompatibility complex regulation of the immune response. Journal of Surgical Research, 1985, 39, 172-181.	0.8	3
466	Mice with GFAP-targeted loss of neurofibromin demonstrate increased axonal MET expression with aging. Glia, 2007, 55, 723-733.	2.5	3
467	The taxonomy of brain cancer stem cells: what's in a name?. Oncoscience, 2014, 1, 241-247.	0.9	3
468	NF GEMMs Already! The Power and Promise of Mouse Tumor Models. Cancer Cell, 2014, 26, 596-599.	7.7	3

#	Article	IF	Citations
469	Exploring the genetic basis for clinical variation in neurofibromatosis type 1. Expert Review of Neurotherapeutics, 2016, 16, 999-1001.	1.4	3
470	Familial Lipomas Without Classic Neurofibromatosis-1 Caused by a Missense Germline NF1 Mutation. Neurology: Genetics, 2021, 7, e582.	0.9	3
471	NFB-09. ENROLLMENT AND CLINICAL CHARACTERISTICS OF NEWLY DIAGNOSED, NEUROFIBROMATOSIS TYPE 1 ASSOCIATED OPTIC PATHWAY GLIOMA (NF1-OPG): PRELIMINARY RESULTS FROM AN INTERNATIONAL MULTI-CENTER NATURAL HISTORY STUDY. Neuro-Oncology, 2020, 22, iii419-iii419.	0.6	3
472	Neurofibromatosis-1 Gene Mutational Profiles Differ Between Syndromic Disease and Sporadic Cancers. Neurology: Genetics, 2022, 8, .	0.9	3
473	Neurofibromatosis type 1. , 2004, , 42-49.		2
474	Modeling Human Brain Tumors in Mice. Brain Pathology, 2009, 19, 108-111.	2.1	2
475	Neurofibromatosis and other genetic syndromes. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 105, 569-582.	1.0	2
476	Teaching Neuro Images : T2 hyperintensities in neurofibromatosis type 1. Neurology, 2013, 80, e215-6.	1.5	2
477	Independent NF1 mutations underlie cafÃ©-au-lait macule development in a woman with segmental NF1. Neurology: Genetics, 2018, 4, e261.	0.9	2
478	Understanding a complicated Gal-1. Neuro-Oncology, 2019, 21, 1341-1343.	0.6	2
479	Immune cell analysis of pilocytic astrocytomas reveals sexually dimorphic brain region-specific differences in T-cell content. Neuro-Oncology Advances, 2021, 3, vdab068.	0.4	2
480	762 Overexpression of EGFRvIII Potentiates the Development and Aggressiveness of Astrocytomas in an Activated Ras Transgenic Mouse Astrocytoma Model. Neurosurgery, 2001, 49, 525.	0.6	2
481	Regulated temporal-spatial astrocyte precursor cell proliferation involves BRAF signalling in mammalian spinal cord.. Journal of Cell Science, 2012, 125, e1-e1.	1.2	2
482	Characterization of three new intra-I region recombinant mouse strains, B10.ASR7 (H-2 as3), B10.BAR4 (H-2 h6), and B10.BASR1 (H-2 as4). Immunogenetics, 1984, 19, 175-178.	1.2	1
483	Reduction in the effectiveness of social systems as a defense against anxiety. Journal of Career Development, 1993, 20, 85-89.	1.6	1
484	THE DIAGNOSIS AND MANAGEMENT OF NEUROFIBROMATOSIS 1. Neurologist, 1998, 4, 313-326.	0.4	1
485	Molecular genetics of optic glioma: lessons learned from neurofibromatosis-1 genetically engineered mice. Expert Review of Ophthalmology, 2011, 6, 363-369.	0.3	1
486	Neurofibromatoses. , 2015, , 921-933.		1

#	Article	IF	Citations
487	A multidisciplinary approach in neurofibromatosis 1â€“Authors' reply. Lancet Neurology, The, 2015, 14, 30-31.	4.9	1
488	De novo development of gliomas in a child with neurofibromatosis type 1, fragile X and previously normal brain magnetic resonance imaging. Radiology Case Reports, 2016, 11, 33-35.	0.2	1
489	Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1. Neuro-Oncology Advances, 2020, 2, i75-i84.	0.4	1
490	Clinic-based study of plexiform neurofibromas in neurofibromatosis 1. American Journal of Medical Genetics Part A, 2000, 92, 132.	2.4	1
491	Neurofibromatosis type 1. , 2020, , 185-200.		1
492	Children with supratentorial midline pilocytic astrocytomas exhibit multiple progressions and acquisition of neurologic deficits over time. Neuro-Oncology Advances, 2022, 4, vdab187.	0.4	1
493	Age and leadership: Crossâ€cultural observations. Psychoanalytic Inquiry, 1982, 2, 109-120.	0.0	0
494	SEPARATION OF THE IMMUNE RESPONSE GENES FOR LDH-B AND MOPC-173. Transplantation, 1985, 40, 556-562.	0.5	0
495	Congenital nystagmus in a [46,XX/45,X] Mosaic woman from a damily with X-linked congenital nystagmus. American Journal of Medical Genetics Part A, 1992, 43, 897-897.	2.4	0
496	Limitations of magnetic resonance spectroscopy in patients with white matter disease. Annals of Neurology, 1994, 36, 932-932.	2.8	0
497	The Elders of the Kibbutz. International Journal of Aging and Human Development, 2007, 64, 47-65.	1.0	0
498	Using Genetically Engineered Mouse Models to Understand Low-Grade Glioma Development and Growth in Children. Neuromethods, 2012, , 203-215.	0.2	0
499	Corrigendum to â€œThe Learning Disabilities Network (LeaDNet): Using Neurofibromatosis Type 1 [NF1] as a Paradigm for Translational Researchâ€• , 2013, 161, 236-236.		0
500	Neurofibromatosis type I. , 0, , 679-685.		0
501	Using the Neurofibromatosis Tumor Predisposition Syndromes to Understand Normal Nervous System Development. Scientifica, 2014, 2014, 1-14.	0.6	0
502	Caddyshack therapeutics: overcoming glioblastoma adaptation. Neuro-Oncology, 2017, 19, 1429-1431.	0.6	0
503	Reply to â€˜Assembling the brain trust: the multidisciplinary imperative in neuro-oncologyâ€™. Nature Reviews Clinical Oncology, 2019, 16, 522-523.	12.5	0
504	LGG-06. COMPREHENSIVE GENOMIC CHARACTERIZATION AND INTEGRATED CLINICAL ANALYSIS OF LOW-GRADE GLIOMAS IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1. Neuro-Oncology, 2021, 23, i32-i32.	0.6	0

#	Article	IF	Citations
505	Neurofibromatosis 1. , 2007, , 413-423.		0
506	Using Neurofibromatosis Type 1 Mouse Models to Understand Human Pediatric Low-Grade Gliomas. , 2009, , 45-59.		0
507	Pediatric Low-Grade Glioma: The Role of Neurofi bromatosis-1 in Guiding Therapy. Pediatric Cancer, 2012, , 285-294.	0.0	0
508	Neurofibromatosis 1 and 2. , 2006, , 1160-1164.		0
509	Human induced pluripotent stem cell modeling of neurofibromatosis type 1. , 2022, , 1-30.		0
510	Predictors of patient return to a tertiary neurofibromatosis subspecialty clinic. Journal of Pediatrics, 2022, , .	0.9	0
511	LINC-08. Neuro-Oncology tumor board â€“ one-year experience of international collaboration. Neuro-Oncology, 2022, 24, i163-i164.	0.6	0